Tempest Therapeutics, Inc., a clinical-stage biotechnology company, develops small molecule therapeutics to treat cancer. Its clinical-stage lead product candidates include Amezalpat, an oral small molecule selective antagonist of peroxisome proliferator-activated receptor alpha for the treatment of first-line unresectable or metastatic hepatocellular carcinoma; and TPST-1495, a small-molecule dual antagonist of the EP2 and EP4 receptors of prostaglandin E2 for treating various cancers. The company has a collaboration agreement with F. Hoffmann-La Roche Ltd. for the development of Amezalpat into a global first-line randomized study. Tempest Therapeutics, Inc. is headquartered in Brisbane, California. Tempest Therapeutics, Inc. operates as a subsidiary of Inception Sciences, Inc.
Metrics to compare  | TPST  | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies  | Relationship RelationshipTPSTPeersSector  | |
|---|---|---|---|---|
P/E Ratio  | −1.0x | −6.0x | −0.6x | |
PEG Ratio  | −0.03 | 0.13 | 0.00 | |
Price/Book  | 4.5x | 2.7x | 2.6x | |
Price / LTM Sales  | - | 70.7x | 3.4x | |
Upside (Analyst Target)  | −10.2% | 167.9% | 39.1% | |
Fair Value Upside  | Unlock | −5.5% | 5.8% | Unlock |